Lowering the annual cost of semaglutide by 18% or making the current cash price available to all patients would make it cost-effective.

Indian pharmaceutical giant Dr Reddy’s Laboratories is gearing up to introduce a generic and significantly cheaper version of Novo Nordisk’s blockbuster weight-loss drug Wegovy. The company’s move ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

Denmark: A study published in Cardiovascular Diabetology has found that patients with overweight or obesity who have prediabetes after a myocardial infarction face a substantially higher risk ...

An AI-designed obesity drug targeting the GIP receptor shows over 31% weight loss in preclinical tests, raising hopes for next-generation metabolic treatments beyond GLP-1 drugs.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Losing weight is no longer just about discipline and diet. GLP-1 drugs are becoming the "fast track" path to weight loss, redefining body and beauty standards for women. | Mind and Body, Lifestyle, ...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and injectable formats at competitive prices. This move aims to ...

Dr Reddy’s Laboratories plans to introduce a generic version of Wegovy in India at a significantly reduced price. With the ...

Find out more about how tirzepatide performed better than semaglutide in weight reduction in a 2026 network meta-analysis.

Experts explain how GLP-1 drugs like Ozempic and Mounjaro work for obesity and weight loss, who should use them, side effects, costs in India, and why they must be treated as medical tools.

Victory Square Technologies Inc. (CSE: VST) (FSE: 6F6) (OTC Pink: VSQTF) (“Victory Square” or the “Company”) provides a ...